Abstract: O-anisamide compounds and their addition salts effective for the prevention and/or therapy of metabolic diseases such as hyperlipidemia and diabetes, in which peroxisome proliferator-activated receptor (PPAR) being intranuclear receptor, in particular, human PPAR participates, as agonistic drugs thereon, and processes for preparing them, wherein the o-anisamide compounds are represented by a general formula (1) [wherein R denotes a carboxyl group, carboxymethyl group or CH2CHXCOY (here X denotes a mercapto group or S(O)nMe (n=0, 1 or 2) and Y denotes an amino group or hydroxyl group)], their medicinally acceptable salts, and their hydrates.

Abstract: A controlled-release pharmaceutical preparation of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine. The controlled-release preparation is in the form of powder or granule containing 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine, coated with medically non-active substance or in the form of rectal suppository containing 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine. Further the controlled-release is prepared by implanting 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine in fatty materials, or granulating it and coating the resultant particles with medically non-active substance.